Bristol-myers Squibb Compnay

Medimmune Limited

Duke University

Bristol-myers Squibb

Michael A Bowen

Ralph Raymond Minter

Alejandro A Aruffo

Barton F Haynes

Jian Chen

Herren Wu

Anthony W Siadak

Chandra S Ramanathan

Vahe Bedian

Steven G Nadler

William Dall'Acqua

Hans Marquardt

Andrew Grier Buchanan

Dhavalkumar D Patel

Michael G Neubauer

Julie Carman

Jeffrey Brown

Pin Lu

Pamela M Carroll

Hong Xiao

Jurgen Bajorath

Anthony Coyle

Steven Rust

Koustubh Ranade

Yihong Yao

Katie Streicher

Gianluca Carlesso

Julie Ann Douthwaite

Robert W Georgantas, Iii

Lydia Greenlees

John E Skonier

Cyril V Privezentzev

Gary C Starling

Dale L Bodian

Jonathan Jacobs

Jacques Moisan

Bahija Jallal

Chris Stannard

Bo Guan

Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.

Stabilized angiopoietin-2 antibodies and uses thereof

Disclosed herein is a method for producing a recombinant polypeptide in a mammalian cell culture in which the mammalian cells have a modified microRNA activity level. In one embodiment, a microRNA activity level is increased. In another embodiment, a microRNA activity level is decreased. In a more particular embodiment, the mammalian cells have a reduced miRNA-let-7a activity level.

Recombinant polypeptide production

Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.

CTLA-4 variants

The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonization) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.

Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease

The present invention is directed to polynucleotides encoding polypeptides associated with the development of rheumatoid arthritis and homologs thereof. The invention further relates to diagnostic and therapeutic methods for utilizing these polynucleotides and polypeptides in the diagnosis, treatment, and/or prevention of rheumatoid arthritis and related disease states. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention, and compounds identified thereby.

Polynucleotides and polypeptides associated with the development of rheumatoid arthritis

The present invention provides novel polynucleotides encodingDmTNF polypeptides, fragments and homologs thereof. The present invention also is directed to novel polynucleotides encoding twoDmTNF variants, DmTNFv1 and DmTNFv2 polypeptides, fragments and homologs thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention, in addition to methods of genetically modifyingor cultured cells to express or mis-express DmTNF, DmTNFv1, or DmTNFv2. The invention also relates to the use of such modified insects or cells to characterize DmTNF activity, identify TNF-like genes and/or genes implicated in modulating TNF, characterize TNF signaling pathways, and/or to identify modulators of DmTNF activity.

[object Object]

The present invention provides novel polynucleotides encodingDmTNF polypeptides, fragments and homologs thereof. The present invention also is directed to novel polynucleotides encoding two Drosophila DmTNF variants, DmTNFv1 and DmTNFv2 polypeptides, fragments and homologs thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention, in addition to methods of genetically modifying Drosophila or cultured cells to express or mis-express DmTNF, DmTNFv1, or DmTNFv2. The invention also relates to the use of such modified insects or cells to characterize DmTNF activity, identify TNF-like genes and/or genes implicated in modulating TNF, characterize TNF signaling pathways, and/or to identify modulators of DmTNF activity.

Drosophila tumor necrosis factor class molecule polynucleotides and variants thereof

The invention provides antibodies and other binding agents that bind specifically to SRCR domains of human CD6 (hCD6) and have advantageous properties, including the capacity to substantially inhibit binding of activated leukocyte adhesion molecule (ALCAM) to hCD6. The binding agents of the invention are useful, inter alia, in methods for screening peptides and drugs that also bind to hCD6 and/or modulate ALCAM binding to hCD6, as well as in diagnostic and therapeutic methods for management and treatment of inflammatory and autoimmune diseases.

Monoclonal antibodies to human CD6

The present invention relates, in general, to CD6 and, in particular, to a CD6 ligand present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cell types. The invention further relates to methods of inhibiting the interaction of CD6 and the CD6 ligand, and to methods of screening compounds for their ability to inhibit that interaction. The invention also relates to antibodies, and binding fragments thereof, specific for CD6 ligand.

Anti-CD6 ligand antibodies

The present invention relates to an isolated nucleic acid molecule having a sequence that encodes a CD6 ligand present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cell types. The invention further relates to a construct containing the nucleic acid molecule and to a host cell comprising same. Further, the invention relates to a method of producing a CD6 ligand.

CD6 ligand encoding sequence

Growing community of inventors

Lawrenceville, NJ, United States of America

Michael A Bowen